What you can and can’t expect from biosimilars.

Update: 2022-10-26

Description

Guest: Sr. Vice President, Optum Rx Clinical and Formulary Services, Savitha Vivian. Long established in Europe, biosimilar alternatives to popular and costly biologic drugs are finally poised to make an impact in the U.S. With biosimilar alternatives to Humira now launching, what does that mean for prescription drug spending?

Comments

In Channel

Revolutionizing pharmacy with AI and Advanced Technologies

2025-11-0617:42

Drug Pipeline Insights: Treatments Poised to Make an Impact

2025-10-1321:14

The Impact of AI on Today's Pharmacy Benefits

2025-06-2517:16

The Big Picture on Pharmacy

2025-05-0517:01

New solutions to help bend the cost curve

2025-03-1020:23

The State of Pharmacy Regulations

2024-11-1419:33

Biosimilars boom: The next era of adoption

2024-09-1317:58

Connections that count: Redefining the PBM experience

2024-04-3022:58

The New Drugs Plan Sponsors Need to Watch For

2024-02-1333:08

Preparing For the Gene Therapy Era

2023-11-0722:51

Making the Invisible Visible: Why Health Equity Matters

2023-10-0427:09

How Choice and Transparency are Changing the PBM Industry

2023-05-3118:29

The Seismic Shift in Weight Loss Medicines

2023-03-2924:13

What you can and can’t expect from biosimilars.

2022-10-2612:34

What’s happening in Specialty Pharmacy?

2022-09-1415:42

00:00

1.0x

What you can and can’t expect from biosimilars.

#box-pro-ellipsis-176372705767954{-webkit-line-clamp:2;}What you can and can’t expect from biosimilars.

What you can and can’t expect from biosimilars.

Optum Rx

What you can and can’t expect from biosimilars.